- Virtual Meeting: Summit Adult Vaccine Recommendations Review (SAVRR) Council hosts first 1-hour open webinar June 9 at 2:00 p.m. (ET) to share its purpose in supporting affordable access and use of vaccinations recommended by healthcare professional organizations
- Vaccine Integrity Project releases results of literature review supporting the safety and effectiveness of Tdap vaccination during pregnancy
- Yale School of Public Health launches web page offering information sheets about vaccines needed during pregnancy
- “Increase in Travel-Associated and Locally Acquired Dengue Cases—United States, 2024” published in MMWR
- Measles 2026: 1,893 confirmed cases this year; Utah outbreak continues
- Measles summit meeting of 15 organizations identifies needs to help healthcare professionals address ongoing outbreaks
- Vaccines in the news
- Medscape offers educational activity on viral hepatitis; CE credit offered
- CHOP’s Vaccine Education Center launches short film, Pennsylvania: At the Forefront in the Prevention of Infectious Diseases, to celebrate America250
- From the Immunize.org shop! Laminated VIS QR code tables deliver CDC VISs directly to your patients’ smartphone (Spanish translation available).
- “Effectiveness of Nirsevimab Immunisation After Birth Versus RSVpreF Maternal Vaccination in Preventing RSV-Related Hospitalisations in Infants: A Population-Based Retrospective Cohort Study” published in Lancet
- "Intramuscular Immunoglobulin for Measles Postexposure Prophylaxis" published in NEJM Evidence
- "State-Level Differences in Human Papillomavirus Vaccine Uptake Among 13- to 17-Year-Old Adolescents" published in JAMA Pediatrics
- Virtual: North Dakota State University Center for Immunization Research and Education hosts webinar titled “2026 US Measles Outbreak: How Did We Get Here and How Do We Get Out of This?” on May 20 at 1:00 p.m. (ET); CE credit offered
- Virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about our Vaccine Confidence & Addressing Concerns web content on June 10 at 4:00 p.m. (ET) or June 11 at 12:00 p.m. (ET). Recorded sessions archived.
Vaccinators and vaccine recipients face unprecedented challenges as vaccination recommendations of federal, state, and healthcare professional organizations proliferate and diverge. The Summit Adult Vaccination Recommendations Review (SAVRR) Council is an independently funded committee of the National Adult and Influenza Immunization Summit (NAIIS), known as “the Summit,” dedicated to supporting implementation of evidence-based vaccination recommendations in this new environment.
The SAVRR Council will host its first public webinar online 2:00–3:00 p.m. (ET) on June 9.
The SAVRR Council is composed of a broad range of voting member organizations and observers whose representatives have been screened by their organizations for conflicts of interest. All participating organizations and their representatives are listed at the SAVRR web page. Vaccine manufacturers and trade organizations do not participate in SAVRR meetings and do not provide any financial support for the Council. The objectives of the SAVRR Council are twofold:
- Serve as a forum to provide practical, diverse stakeholder feedback to organizations making vaccination recommendations
- Support clinical implementation of evidence-based vaccination recommendations by identifying challenges to implementation and recommending strategies to increase affordable access and vaccine use
- NAIIS main page
- SAVRR Council main page
- SAVRR Council Member Organizations (PDF)
Vaccine Integrity Project releases results of literature review supporting the safety and effectiveness of Tdap vaccination during pregnancy
The University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) launched the Vaccine Integrity Project (VIP) in 2025 to support U.S. vaccine policies and practices that are grounded in scientific evidence. The VIP engages with healthcare providers, public health professionals, and medical societies to provide science-based information for informed vaccine choices. Medical societies that release vaccine recommendations, such as the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP), are using VIP meta-analyses, like this one, to inform their recommendation deliberations.
On May 13, the VIP released a systematic review and meta-analysis on the safety and effectiveness of Tdap vaccination during pregnancy. A portion of the abstract appears below:
Vaccination with Tdap during pregnancy likely protects infants against pertussis infection, complications due to pertussis, and death due to pertussis. Results also demonstrated no meaningful difference in risk of stillbirth, preterm birth, preeclampsia and eclampsia, chorioamnionitis, and other adverse pregnancy outcomes in study populations who received Tdap during pregnancy compared to those who did not. Additionally, we found no meaningful difference in risk of adverse neonatal outcomes such as mortality, continental [sic, congenital] anomalies, growth restriction, and NICU admission. When Tdap vaccination is provided during the currently recommended 27-36 weeks’ gestation of pregnancy, it is safe and effective.
Related Links
- VIP: Safety and Effectiveness of Tetanus-Diphtheria-Acellular Pertussis (Tdap) Vaccination During Pregnancy: A Systematic Review and Meta-Analysis (PDF)
- VIP: Tdap Vaccine in Pregnancy main page
- Immunize.org: Vaccines A–Z: Tetanus main page
- Immunize.org: Vaccines A–Z: Diphtheria main page
- Immunize.org: Vaccines A–Z: Pertussis main page
The Yale School of Public Health launched a Vaccines During Pregnancy web page with downloadable information sheets (English and Spanish) to answer common questions about vaccination during pregnancy. Based on real-world conversations, questions include:
- Which vaccines are recommended during pregnancy?
- How do we know these vaccines are safe for both me and my baby?
- Why are certain prenatal vaccines recommended during different trimesters? Does the timing and spacing of these vaccines matter?
- The last time I got vaccinated, I still got sick. Why should I get vaccinated now that I’m pregnant?
- I still need more information to feel confident about prenatal vaccines. Where can I go for more information?
Information sheets are available for download in English and Spanish.
Back to top“Increase in Travel-Associated and Locally Acquired Dengue Cases—United States, 2024” published in MMWR
CDC published Increase in Travel-Associated and Locally Acquired Dengue Cases—United States, 2024 on May 14 in MMWR. One dengue vaccine (Dengvaxia, Sanofi) is licensed and recommended in the United States for children residing in dengue-endemic areas who have a laboratory-confirmed history of previous dengue infection; the manufacturer discontinued production due to lack of use. There is no dengue vaccine recommended for U.S. travelers. A portion of the summary appears below.
Dengue is a leading cause of febrile illness in travelers returning from regions where the virus is endemic. . . .
During 2024, the number of dengue cases reported from U.S. states and the District of Columbia increased 359% above the annual average during 2010–2023; a total of 97.2% of cases were travel associated, and 2.8% were locally acquired. Approximately one fifth (21.8%) of cases occurred among persons aged 50–59 years, and more than one half (57.5%) occurred in Hispanic or Latino persons. Approximately one third (36.1%) of patients were hospitalized; six (0.2%) patients died. . . .
The sharp increase in travel-associated dengue highlights an urgent need for enhanced prevention strategies, improved clinical awareness, and tailored messaging for travelers to areas with ongoing dengue transmission.
Access the MMWR article in HTML or PDF.
Related Links
- CDC: MMWR main page providing access to the MMWR family of publications
- Immunize.org: Vaccines A–Z: Dengue main page
As of May 14, CDC reported 51 new measles cases in the previous week, reaching 1,893 confirmed measles cases for 2026, with all but 9 cases infected in the United States. So far, 39 jurisdictions have reported measles cases in 2026.
The measles outbreak that originated along the Utah-Arizona border is the largest active outbreak at this time.
- The Utah Department of Health and Human Services reports 663 cases since January 2026
- The Arizona Department of Health and Human Services confirmed 315 cases in 2026, most linked to the Utah outbreak
Below is a map from CDC showing measles cases among U.S. residents as of May 14.
Vaccine coverage rates may vary considerably from community to community within a state. Pockets of unvaccinated people can accumulate in states with high vaccination coverage, creating conditions favorable for an outbreak if measles is introduced. Vaccination remains extremely effective. Immunize.org offers measles-related resources for the public on several of our affiliated websites:
- VaccineInformation.org: Measles web page
- LetsGetRealAboutVaccines.org: Measles web page
- Immunize.org: Vaccines A–Z: Measles main page
- AAP: Fact Checked: The MMR (Measles, Mumps and Rubella) Vaccine Is Safe and Effective web page
- CDC: Measles Cases and Outbreaks main page
- Common Health Coalition: More Illness, Greater Cost: Spotlight Brief; Childhood Immunizations (PDF)
- Johns Hopkins International Vaccine Access Center: U.S. Measles Tracker web page
- PopHIVE (Yale School of Public Health): Infectious Diseases Dashboard: Measles web page
- Health Canada: Measles and Rubella Weekly Monitoring Report
Measles summit meeting of 15 organizations identifies needs to help healthcare professionals address ongoing outbreaks
NFID and the Infectious Diseases Society of America (IDSA) convened 15 healthcare professional societies for a Measles Summit in San Diego May 7–8. Their event identified several ways to help healthcare professionals address ongoing measles outbreaks in the United States. Priority needs defined by the group included:
- Updated clinical guidance and education incorporating emerging research on the clinical impact and long-term complications of measles infection, and considerations for pregnancy, neonatal, and pediatric care;
- Readily accessible, actionable resources and decision-support tools for healthcare professionals across settings responding to measles cases, from schools and urgent care centers to clinics and hospitals;
- Updated healthcare system preparedness and infection control approaches informed by lessons learned from recent outbreaks and applicable across healthcare settings;
- State and local public health resources for outbreak response and case management tailored to the needs and realities of affected communities;
- Protocols for following measles cases and understanding the long-term complications;
- Communication approaches that incorporate community voices so that healthcare and public health professionals can work together to address local questions and concerns, educate about the impact of measles and underscore the importance of immunization in protecting children and families from measles
Participants intend to collaborate to develop resources and disseminate practical tools to support measles prevention and response.
Related Link
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
- CIDRAP: The State of US Vaccine Policy (5/14/26)
- The Guardian: US Government Studies into Vaccine Safety Are Being Suppressed (5/12/26)
- Time: The Long-Term Measles Complication Most People Don't Know About (5/11/26)
- The Hill: Congress Built the Vaccine Firewall. Now Congress Must Defend It. (5/11/26)
This week’s spotlight features recommended immunization schedules from CDC as well as healthcare professional organizations.
Schedules are found in the “Official Guidance” menu, both under the “CDC” and “Healthcare Professional Organizations” left-hand submenus.
The CDC Recommended Schedules page features the 2025 official recommended immunization schedules from CDC for children, adolescents, and adults. You can view or download PDF versions of the schedules, link to them on the CDC website, or download a schedules app for mobile devices.
Healthcare professional organizations that do not endorse recent changes to vaccination recommendations published by CDC issued their own schedules for the populations they serve.
Our Healthcare Professional Organization Schedules page displays schedules from the American Academy of Pediatrics (AAP) and the American Academy of Family Practitioners (AAFP). AAP offers a pediatric schedule. AAFP offers two schedules, one for adults and one for birth through age 18 years that is consistent with the AAP schedule. Links to view or download the PDF versions as well as links to their websites are provided.
Related Link
- Immunize.org: Healthcare Professional Organization Vaccine Recommendations and Schedules (3:42)
Recap: Immunize.org reviews and updates “Ask the Experts: Vaccine Safety” questions and answers section
Immunize.org reviewed its Ask the Experts: Vaccine Safety section. No content required major changes. Several hyperlinks were updated.
Immunize.org’s Ask the Experts main page leads you to 30 web pages on various topics with more than 1,300 common or challenging questions and answers about vaccines and their administration. Immunize.org’s team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane Zucker, MD, MSc.
Related Links
- Immunize.org: Ask the Experts main page with more than 1,300 questions and answers
- Immunize.org: Ask the Experts: Vaccine Safety web page
Medscape Education released a curriculum, Targeting Viral Hepatitis: A Road Map for Providers, with several activities featuring expert perspectives on preventing and managing viral hepatitis.
The activities include:
- Closing the Loop: Smarter Workflows for Hepatitis Screening and Prevention: How can clinicians engage patients in discussions about viral hepatitis? (30 min)
- Are Your Workflows Working? Embedding Hepatitis Screening and Vaccination into Routine Care: Protect your patients against viral hepatitis. (15 min)
- How Do You Stack Up? Case Challenges in Guideline-Based Management of Viral Hepatitis: Assess your ability to screen for hepatitis B and hepatitis C. (60 min)
The curriculum titled "Are Your Workflows Working? Embedding Hepatitis Screening and Vaccination into Routine Care" was codeveloped and moderated by Immunize.org’s L.J Tan, PhD. A description of the curriculum appears below.
Despite advances in effective therapies, viral hepatitis rates continue to increase, especially among certain communities, identified as priority health populations. These populations include people who inject drugs (PWID), Asians and Pacific Islanders, American Indians/Alaska Natives, and non-Hispanic Black persons. Furthermore, systemic barriers, stigma, and discrimination impede access to health services for people at increased risk for viral hepatitis. These factors contribute to missed/late diagnosis, onward transmission, costly tertiary care, and reduced quality of life. This collection of CME-certified activities provides strategies to overcome barriers and deliver equitable care to further the achievement of hepatitis elimination goals in the United States and worldwide.
To earn CME, ABIM MOC, or CE credit, please click here.
The Vaccine Education Center (VEC) at Children’s Hospital of Philadelphia (CHOP) posted a short film, Pennsylvania: At the Forefront in the Prevention of Infectious Diseases, to commemorate the 250th anniversary of America’s founding. A summary of the film appears below.
At this important milestone in our nation’s history, take a look back at the state where the Declaration of Independence was born and honor Pennsylvania’s contributions to independence from the wraths of infectious diseases like smallpox, COVID-19 and many others.
The 7 1/2-minute film highlights Pennsylvania as an epicenter of vaccine science from the Revolutionary War to today and celebrates the many public health contributions from PA-affiliated scientists. After watching the film, try your hand on our word scramble puzzle to reveal a public health message.
VISs explain both risks and benefits of vaccination. Federal law requires you to document provision of CDC’s current VIS before administering any vaccine covered by the Vaccine Injury Compensation Program. CDC recommends VISs accompany other vaccines, too. An easy, paperless way to comply with the law is for patients to scan a QR code and access the VIS from a smartphone or tablet.
CDC produces official VISs only in English. CDC does not produce or certify available translations, so the official CDC VIS should accompany any translation.
These new tables belong in any room where vaccinations are given. Key features include:
- Never out-of-date: Any time a VIS or translation is updated, the QR code links to the new VIS.
- Use as booklet or poster: The laminated table arrives folded like a newspaper. It is suitable for desk use as an 8.5" x 11" booklet or wall mounted as an 11" x 17" poster.
- One version for official CDC VISs and one for Spanish translations: The table of VISs in English is sold individually. The table of Spanish translations is sold as a bundle with the table of official VISs so it is easy to make both available.
- Spanish version usable by non-Spanish speakers: The Spanish QR code table has side-by-side text in English to support its use by non-Spanish speakers.
- Easy access to all available translations: Both versions include a QR code link to the Immunize.org index of all VIS translations available in dozens of languages.
- Bonus content: The reverse side of the QR code poster includes links to Immunize.org's “Addressing Vaccination Anxiety” resources and additional VIS content.
Pricing (includes all shipping and handling costs)
| Laminated CDC VIS QR Code Table (English) | Bundle: Laminated CDC (English) + Spanish Translation VIS QR Code Tables (includes 1 CDC VIS table and 1 table of translations) |
| 1 copy: $14.00 | 1 bundle: $20.00 |
| 2 copies: $9.00 each | 2 bundles: $16.00 each |
| 3–4 copies: $6.50 each | 3–4 bundles: $12.00 each |
| 5–9 copies: $5.00 each | 5–9 bundles: $8.50 each |
| 10–19 copies: $4.00 each | 10–19 bundles: $7.00 each |
| 20–59 copies: $3.00 each | 20–59 bundles: $6.00 each |
| 60+ copies: $2.50 each | 60+ bundles: $5.00 each |
Visit the Shop Immunize.org: Laminated VIS QR Code Tables web page to view images and order today! For additional information, call 651-647-9009 or email admininfo@immunize.org.
In its May 7 issue, Lancet published Effectiveness of Nirsevimab Immunisation After Birth Versus RSVpreF Maternal Vaccination in Preventing RSV-Related Hospitalisations in Infants: A Population-Based Retrospective Cohort Study. Portions of the methods, findings, and interpretation sections appear below.
This population-based retrospective cohort study used data from the French National Health Data System and included all children born across metropolitan France between Sept 1, 2024, and Feb 28, 2025, who either received nirsevimab at birth (nirsevimab group) or whose mothers received RSVpreF vaccine [Abrysvo, Pfizer] between 28 weeks and 36 weeks of gestation (RSVpreF group). . . . The primary outcome was RSV-related LRTI [lower respiratory tract infection] hospitalisation at age 6 months. Propensity score analysis adjusted for baseline characteristics. . . .
. . . During the 6-month follow-up, 753 RSV-related LRTI hospitalisations occurred: 350 (0·83%) of 42 098 infants in the nirsevimab immunisation group and 403 (0·96%) of 42 098 infants in the RSVpreF vaccine group. After adjustment, nirsevimab was associated with a 22% reduction in the odds of RSV-related LRTI hospitalisation compared with RSVpreF vaccination (OR 0·78 [95% CI 0·70–0·86]). . . . there was no difference between nirsevimab and RSVpreF given 8 weeks or more before delivery (1·01 [0·77–1·32]).
Compared with RSVpreF maternal vaccine, nirsevimab at birth was associated with a reduction in the odds of RSV-related LRTI hospitalisation at age 6 months in the 2024–25 RSV season. Exploratory secondary analyses suggest that an interval of at least 8 weeks between RSVpreF vaccination and delivery could provide protection not statistically different from nirsevimab at birth. These findings can guide future public health decisions.
On May 13, NEJM Evidence published Intramuscular Immunoglobulin for Measles Postexposure Prophylaxis. This is one in a series of Public Health Alerts published in partnership with the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP). The abstract appears below.
Intramuscular immunoglobulin (IMIG) administered at a dose of 0.5 ml/kg is an option for prophylaxis in infants after exposure to measles. The weight-based dosing volumes require multiple or large-volume injections; however, no clear administration guidelines exist. In 2025, the Utah Department of Health and Human Services (DHHS) assisted with coordination of IMIG administration after an exposure event at a pediatric clinic. Utah DHHS worked with the local health department and health care facility to develop a plan for administration that has been used in subsequent exposure events in Utah.
In its May 11 issue, JAMA Pediatrics published State-Level Differences in Human Papillomavirus Vaccine Uptake Among 13- to 17-Year-Old Adolescents. The abstract appears below.
Despite gains in human papillomavirus (HPV) vaccine uptake among adolescents in the United States and the availability of the vaccine for children as young as 9 years, coverage remains suboptimal and below the Healthy People 2030 goal of 80%, with the South census region demonstrating lower uptake than other regions. In their study to examine HPV vaccine uptake among adolescents from 2019 to 2021, Ejezie et al found that uptake in the South census region lagged behind that of the West. While this regional insight is valuable for researchers developing strategies to address low HPV vaccination rates, the absence of a clearly delineated state-level analysis limits its practical application. Examining uptake at the state level could help identify state-specific determinants and better inform the design of targeted interventions.The North Dakota State University (NDSU) Center for Immunization Research and Education will host a webinar titled 2026 US Measles Outbreak: How Did We Get Here and How Do We Get Out of This? at 1:00 p.m. on May 20. During this webinar, Patsy Stinchfield, RN, PNP, an expert in infectious diseases and immunization, will review vaccination trends, clinical management, and post-exposure prophylaxis with immune globulin. Participants will also learn infection control strategies and practical resources to address vaccine misinformation, equipping them with tools to help stop the spread.
This activity is approved for free CME and CPE credit.
Register for the webinar.
To learn simple tips and tricks for using our websites efficiently, please register for our next set of Website Office Hours on Wednesday, June 10, at 4:00 p.m. (ET) or Thursday, June 11, at 12:00 p.m. (ET). The same content will be covered in both sessions.
We will open each 30-minute session with a short, live demonstration on navigating our Vaccine Confidence & Addressing Concerns website section. You can submit questions when you register or live on Zoom during the session.
Register today for Immunize.org Website Office Hours (content is the same for both):
The archive of previous Website Office Hours content is posted at Immunize.org’s "Webinars & Videos" page.
Mark your calendar for future Immunize.org Website Office Hours.
For more upcoming events, visit our Calendar of Events.